Rytary (formerly known as IPX066) consist of carbidopa and levodopa extended-release capsules for early, moderate, and advanced Parkinson’s Disease (PD) treatment. The drug has been approved by the U.S. Food and Drug Administration (FDA) in 2015.

The combination of carbidopa and levodopa is one of the most commonly used drug combinations to treat the symptoms of PD. Rytary is a singular formulation of carbidopa and levodopa, which provides a  longer and more stable mode of action compared to regular carbidopa and levodopa combinations.

How Rytary works

Rytary capsules are manufactured so that they contain beads that release carbidopa and levodopa at different speeds as they are dissolved in the stomach. Their absorption occurs over a prolonged period of time.

Carbidopa decreases the body’s conversion of levodopa so that more levodopa can reach the brain, where it is converted into dopamine by nerve cells to replenish the brain’s supply.

Rytary research

Clinical studies have shown that people with early PD using Rytary had a significant improvement in the ability to move and perform activities during the day, while people with advanced PD experienced much less “off” periods, with more “on” periods without uncontrollable movements during the day. (“Off” periods are when the medication is not working, making movements harder. “On” periods are when the symptoms are less apparent and mobility is better).

Other details

Rytary capsules are to be taken by mouth with or without food.

Nonselective monoamine oxidase (MAO) inhibitors and antidepressants should not be taken with Rytary capsules and a period of two weeks should be allowed between Rotary and these drugs to prevent blood pressure increases.

Some multivitamin supplements or medications with iron may decrease the absorption of Rytary capsules, as may some high-protein and high-fat foods.

Rytary capsules should not be stopped suddenly as this may lead to complications.

Common side effects associated with the use of the drug are abnormal dreams, constipation, dizziness, drowsiness, dry mouth, headache, nausea, trouble sleeping, and vomiting.

Note: Parkinson’s News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.